Skip to main content

Table 3 Six overlapping SNPs in PPARGC1B associated with ER-positive breast cancer in Swedish and Finnish samples

From: Genetic variation of ESR1 and its co-activator PPARGC1B is synergistic in augmenting the risk of estrogen receptor-positive breast cancer

SNP Allelea Subtype Swedish sample Finnish sample
    MAFb ORc (95% CI) MAFb ORc (95% CI)
rs4705365 G/A ER+ 0.21 1.26 (1.05, 1.52) 0.17 1.26 (1.05, 1.52)
   ER-   1.14 (0.81, 1.61)   1.17 (0.9, 1.52)
   All cases   1.14 (0.97, 1.33)   1.18 (0.99, 1.4)
rs6895698 G/A ER+ 0.22 1.27 (1.06, 1.53) 0.17 1.39 (1.15, 1.67)
   ER-   1.05 (0.74, 1.48)   1.14 (0.88, 1.49)
   All cases   1.12 (0.96, 1.3)   1.25 (1.05, 1.49)
rs2340621 G/A ER+ 0.31 1.3 (1.08, 1.57) 0.32 1.22 (1.03, 1.46)
   ER-   0.86 (0.61, 1.2)   1.05 (0.82, 1.34)
   All cases   1.12 (0.96, 1.31)   1.14 (0.97, 1.34)
rs10036538 C/G ER+ 0.26 1.19 (0.99, 1.42) 0.22 1.2 (1, 1.43)
   ER-   0.91 (0.65, 1.28)   1.05 (0.81, 1.35)
   All cases   1.03 (0.89, 1.2)   1.11 (0.94, 1.31)
rs1012543 A/G ER+ 0.26 1.26 (1.05, 1.51) 0.23 1.26 (1.06, 1.5)
   ER-   1.08 (0.77, 1.51)   1.08 (0.84, 1.38)
   All cases   1.11 (0.95, 1.29)   1.18 (1, 1.39)
rs741581 G/A ER+ 0.08 1.32 (1.05, 1.67) 0.05 1.76 (1.33, 2.31)
   ER-   0.81 (0.49, 1.32)   1.21 (0.81, 1.82)
   All cases   1.12 (0.92, 1.37)   1.53 (1.18, 1.98)
  1. ER+, estrogen receptor-positive; ER-, estrogen receptor-negative; MAF, minor allele frequency; OR, odds ratio; CI, confidence interval. aMajor allele/minor allele. bFrom control samples only. cORs were performed on a dominant model, age-unadjusted analysis in the Swedish sample and age-adjusted analysis in the Finnish sample.